Before the BARDA funding grant the share price was roughly $1. Even though this stockmarket is totally irrational, it is rational to say that the BARDA funding was NOT built into that low, suppressed shareprice of $1
Now we have $250 million BARDA funding and the shareprice has increased 30 cents to now be at around $1.30. Biota's market capitalisation has increased from $185 million to $240 million.
So a $250 million BARDA grant (with the end major 'prize' being the preferred supplier of the very significant US government stockpiling market) is valued today by the stockmarket to be worth $55 million.
$250 million + $x = $55 million
Does not compute
$250 million BARDA grant + future Inavir stockpiling dollars + strong advanced pipeline of 3 drugs + Inavir Japan royalties + Relenza royalties + $90 million cash in bank equals $??????, however current Market cap = $240 million
Does not compute
Sticklers may 'discount' that 250 million because it is over five years, but it still does not compute.
- Forums
- ASX - By Stock
- BTA
- does not compute
does not compute
Featured News
Add BTA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online